| 000 | 01875 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514190356.0 | ||
| 264 | 0 | _c20041209 | |
| 008 | 200412s 0 0 eng d | ||
| 022 | _a1600-6135 | ||
| 024 | 7 |
_a10.1111/j.1600-6143.2004.00435.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMacPhee, Iain A M | |
| 245 | 0 | 0 |
_aThe influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. _h[electronic resource] |
| 260 |
_bAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons _cJun 2004 |
||
| 300 |
_a914-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aCytochrome P-450 CYP3A |
| 650 | 0 | 4 |
_aCytochrome P-450 Enzyme System _xgenetics |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aKidney _xdrug effects |
| 650 | 0 | 4 | _aKidney Transplantation |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPharmacogenetics |
| 650 | 0 | 4 |
_aPolymorphism, Single Nucleotide _xphysiology |
| 650 | 0 | 4 |
_aTacrolimus _xtherapeutic use |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aFredericks, Salim | |
| 700 | 1 | _aTai, Tracy | |
| 700 | 1 | _aSyrris, Petros | |
| 700 | 1 | _aCarter, Nicholas D | |
| 700 | 1 | _aJohnston, Atholl | |
| 700 | 1 | _aGoldberg, Lawrence | |
| 700 | 1 | _aHolt, David W | |
| 773 | 0 |
_tAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons _gvol. 4 _gno. 6 _gp. 914-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1600-6143.2004.00435.x _zAvailable from publisher's website |
| 999 |
_c14856385 _d14856385 |
||